CureVac

CureVac
Name	CureVac
Type	Public
Founded	2000
Founder	Ingmar Hoerr, Florian von der Mülbe, Steve Pascolo
Headquarters	Tübingen, Baden-Württemberg, Germany
Key people	Franz‑W. Pruckner (CEO), Ingmar Hoerr (co‑founder)
Industry	Biotechnology
Products	mRNA therapeutics, vaccines

CureVac is a biotechnology company based in Tübingen, Baden‑Württemberg, Germany, focused on the development of messenger RNA (mRNA) technologies for vaccines and therapeutics. The company was founded by academic researchers with backgrounds at institutions such as the University of Tübingen, Max Planck Institute for Developmental Biology, and has operated in the context of global public health events including the COVID‑19 pandemic, collaborating and competing with companies like BioNTech, Moderna, and institutions such as the European Medicines Agency. CureVac has pursued both proprietary and partnered programs across infectious disease, oncology, and rare disease indications.

History

CureVac was founded in 2000 by researchers including Ingmar Hoerr, who had worked at the University of Tübingen and published early work on mRNA delivery, and Florian von der Mülbe, with ties to European biotechnology networks such as European Molecular Biology Laboratory. The company grew during the 2000s and 2010s with investments and partnerships involving entities like Deutsche Bank, the European Investment Bank, and strategic collaborations with pharmaceutical firms such as Bayer and Sanofi. CureVac attracted high‑profile attention during the 2019–20 coronavirus pandemic and entered a high‑visibility collaboration and equity agreement with Bayer AG and later with AstraZeneca for manufacturing capacity and development support. In 2020 CureVac announced a landmark collaboration and investment with Volkswagen's founder‑linked entities and received pandemic‑era funding from national and supranational bodies including the German Federal Ministry of Education and Research and the European Commission. The company went public with an initial public offering on the NASDAQ in 2020.

Technology and Products

CureVac's platform centers on synthetic messenger RNA technologies and delivery systems informed by foundational research from laboratories at the University of Tübingen and methods used across the mRNA field by firms such as BioNTech and Moderna. The company developed unmodified and optimized mRNA constructs intended to encode antigens or therapeutic proteins, and lipid nanoparticle (LNP) delivery approaches related to work by researchers at Harvard Medical School and MIT. Product programs included an mRNA vaccine candidate against SARS‑CoV‑2, named CVnCoV, and second‑generation constructs intended to leverage sequence optimization and formulation improvements influenced by advances at institutions like the National Institutes of Health and the German Center for Infection Research. CureVac's pipeline has encompassed infectious disease vaccines, oncology immunotherapies, and protein replacement strategies, parallel to programs at companies such as GlaxoSmithKline and research at the Institute Pasteur.

Clinical Trials and Regulatory Status

CureVac's lead COVID‑19 candidate, CVnCoV, advanced through Phase I/II and Phase IIb/III clinical trials during the global response coordinated with agencies including the European Medicines Agency and national regulators such as the Paul Ehrlich Institute. The Phase IIb/III trial results announced in 2021 showed lower efficacy than contemporaneous mRNA vaccines from Pfizer–BioNTech and Moderna, leading to regulatory reassessment and strategic program changes. CureVac initiated subsequent trials for second‑generation candidates and submitted data packages to regulators while engaging with international initiatives such as the World Health Organization and vaccine procurement frameworks like COVAX. Other therapeutic candidates progressed through early‑phase oncology and rare disease studies overseen by institutional review boards at clinical centers including Charité – Universitätsmedizin Berlin and university hospitals across Europe.

Collaborations and Partnerships

CureVac established multiple strategic partnerships with pharmaceutical and manufacturing organizations: an early research link with Bayer for development and manufacturing; a 2020 equity and collaboration agreement with GSK‑adjacent entities for adjuvant and platform access; manufacturing and scale‑up arrangements with contract manufacturing organizations linked to Novartis‑scale facilities and with firms such as Lonza. The company engaged academic collaborations with universities like the Karolinska Institute and research institutes including the Max Planck Society and the German Center for Neurodegenerative Diseases. Public‑private interactions included funding and coordination with the German Federal Ministry of Health and procurement discussions with multinational initiatives such as CEPI. CureVac also entered licensing negotiations and consortiums involving industry participants such as AstraZeneca and governmental stakeholders in Germany, Austria, and the European Union.

Financial Performance and Ownership

CureVac's financing history includes venture capital rounds, strategic investments, and a 2020 initial public offering on the NASDAQ, which placed the company among European biotech listings like BioNTech's public debut. Major shareholders have included institutional investors and strategic partners; significant investment and collaboration agreements were announced with firms connected to Bayer and with philanthropic or governmental funding sources comparable to investments made by the Bill & Melinda Gates Foundation in global health ventures. Revenue and profitability were affected by clinical outcomes and market dynamics during the COVID‑19 pandemic, prompting corporate restructuring, workforce adjustments, and capital raises. Corporate governance events, board appointments, and leadership changes involved figures experienced in multinational pharmaceutical management and finance.

Controversies and Criticism

CureVac faced criticism and public scrutiny following the Phase IIb/III results for CVnCoV, with commentators comparing outcomes to those of Pfizer–BioNTech and Moderna and raising questions about technological differences, intellectual property, and strategic decisions. Debate involved interpretations of mRNA modification strategies pioneered by groups linked to Katalin Karikó and research at University of Pennsylvania, and discussions about licensing, patents, and technology transfer with companies such as Arcturus Therapeutics and Ionis Pharmaceuticals. Political commentary in Germany and coverage in international media examined procurement choices, pricing, and the role of public funding during the COVID‑19 pandemic, while shareholder disputes and analyst commentary touched on governance and clinical development strategy. Legal and regulatory inquiries centered on trial data disclosure and contractual terms with partners and governments, as observed in other high‑profile biotech cases involving companies like Theranos and Valeant Pharmaceuticals International.

Category:Biotechnology companies of Germany